Tigermed (泰格医疗) A+H: PHIP Updates and Thoughts on Valuation
412 Views20 Jul 2020 18:52
Hangzhou Tigermed, a leading China-based CRO company, is seeking a USD 1.5 bn H-share listing in Hong Kong. In our previous note, we discussed that...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
- Tigermed (泰格医疗) A+H Trading: Insti Buying to Continue Post Listing06 Aug 2020
- Tigermed (泰格医疗) A+H: Past A+H Listings Suggest Upside Might Be Limited27 Jul 2020
- Tigermed (泰格医疗) A+H: PHIP Updates and Thoughts on Valuation20 Jul 2020
- Tigermed (泰格医疗) A+H Listing: Hot Deal of the Best China Clinical-CRO Play26 Apr 2020
x